4.8 Article

A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Rheumatology

Immunogenicity of biologic agents in rheumatology

Vibeke Strand et al.

Summary: Biologic agents have become crucial in treating inflammatory rheumatic diseases, but their immunogenicity can impact treatment response and adverse events. Immunogenicity testing is becoming part of routine clinical management in some fields, with the cost-effectiveness in rheumatology still being studied.

NATURE REVIEWS RHEUMATOLOGY (2021)

Review Engineering, Biomedical

Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics

Yu Chen et al.

Summary: Drug delivery systems based on genetically engineered oncolytic bacteria have unique properties that enable them to target tumor tissues and suppress tumor growth effectively, showing potential value for clinical applications. By integrating oncolytic bacteria into cancer therapies, novel strategies are being developed to improve and standardize current treatment regimens in the near future.

ACTA BIOMATERIALIA (2021)

Review Rheumatology

The gut-joint axis in rheumatoid arthritis

Mario M. Zaiss et al.

Summary: The review discusses the role of intestinal dysbiosis in rheumatoid arthritis and highlights the potential pathogenic role of gut-derived immune cells in the joints. It also explores the hypothesis that alterations in the microbial flora may precede the onset of RA and suggests that modulation of intestinal microbiota could be a potential therapeutic approach for preventing or treating RA.

NATURE REVIEWS RHEUMATOLOGY (2021)

Article Endocrinology & Metabolism

Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study

Marja K. Puurunen et al.

Summary: The engineered E. coli strain SYNB1618 shows potential for the treatment of PKU, as it was safe and well tolerated in a phase 1/2a clinical trial with both healthy volunteers and PKU patients. The study demonstrated dose-responsive increases in strain-specific Phe metabolites in plasma and urine, supporting the proof of concept for using engineered bacteria in the treatment of rare metabolic disorders.

NATURE METABOLISM (2021)

Review Immunology

Immunogenicity of TNF-Inhibitors

Sadaf Atiqi et al.

FRONTIERS IN IMMUNOLOGY (2020)

Article Biotechnology & Applied Microbiology

Challenges and Pitfalls in the Engineering of Human Interleukin 22 (hIL-22) SecretingLactobacillus reuteri

Laura Ortiz-Velez et al.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)

Article Chemistry, Medicinal

Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin

Seow Theng Ong et al.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)

Review Biotechnology & Applied Microbiology

Non-invasive delivery strategies for biologics

Aaron C. Anselmo et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Article Multidisciplinary Sciences

Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut

Pichet Praveschotinunt et al.

NATURE COMMUNICATIONS (2019)

Article Pharmacology & Pharmacy

Targeting KCa1.1 Channels with a Scorpion Venom Peptide for the Therapy of Rat Models of Rheumatoid Arthritis

Mark R. Tanner et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)

Review Microbiology

Role of Lactobacillus reuteri in Human Health and Diseases

Qinghui Mu et al.

FRONTIERS IN MICROBIOLOGY (2018)

Review Endocrinology & Metabolism

Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications

Jae-hyuck Shim et al.

CALCIFIED TISSUE INTERNATIONAL (2018)

Editorial Material Pharmacology & Pharmacy

KCa1.1 channels as therapeutic targets for rheumatoid arthritis

Christine Beeton

EXPERT OPINION ON THERAPEUTIC TARGETS (2017)

Review Biochemistry & Molecular Biology

The Therapeutic Benefit of Bacterial Membrane Vesicles

Natalie J. Bitto et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Article Multidisciplinary Sciences

Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats

Ralf Bergmann et al.

SCIENTIFIC REPORTS (2017)

Article Microbiology

The Potential of Probiotics as a Therapy for Osteoporosis

Fraser L. Collins et al.

MICROBIOLOGY SPECTRUM (2017)

Review Biochemistry & Molecular Biology

Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease

K. George Chandy et al.

CURRENT OPINION IN CHEMICAL BIOLOGY (2017)

Article Chemistry, Medicinal

Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa

Liang Jin et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2016)

Article Chemistry, Medicinal

Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases

Liang Jin et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2016)

Review Medicine, General & Internal

Rheumatoid arthritis

Josef S. Smolen et al.

LANCET (2016)

Article Chemistry, Medicinal

Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK

Michael W. Pennington et al.

MARINE DRUGS (2015)

Review Chemistry, Multidisciplinary

Enhancing the Buccal Mucosal Delivery of Peptide and Protein Therapeutics

Thiago Caon et al.

PHARMACEUTICAL RESEARCH (2015)

Review Biochemistry & Molecular Biology

Domain structure and function of matrix metalloprotease 23 (MMP23): role in potassium channel trafficking

Charles A. Galea et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2014)

Article Cell Biology

Probiotic L. reuteri Treatment Prevents Bone Loss in a Menopausal Ovariectomized Mouse Model

Robert A. Britton et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2014)

Article Biotechnology & Applied Microbiology

Engineering Signal Peptides for Enhanced Protein Secretion from Lactococcus lactis

Daphne T. W. Ng et al.

APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2013)

Review Immunology

Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature

Bart J. F. van den Bemt et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)

Article Pharmacology & Pharmacy

Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease

Eric J. Tarcha et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)

Article Multidisciplinary Sciences

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases

Christine Beeton et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

Article Medicine, Research & Experimental

The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS

H Wulff et al.

JOURNAL OF CLINICAL INVESTIGATION (2003)

Article Biochemistry & Molecular Biology

A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes

C Beeton et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

Article Multidisciplinary Sciences

Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis

C Beeton et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)